logo
Securities Fraud Investigation Into Easterly ROCMuni High Income Municipal Bond Fund (RMHIC, RMHVX, RMJAX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Easterly ROCMuni High Income Municipal Bond Fund (RMHIC, RMHVX, RMJAX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--Jul 24, 2025--
The Law Offices of Frank R. Cruz announces an investigation of Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund ('Easterly' or the 'Fund') (NASDAQ: RMHIX, RMHVX, RMJAX ) on behalf of investors concerning the Fund's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON EASTERLY ROCMUNI HIGH INCOME MUNICIPAL BOND FUND (RMHIC, RMHVX, RMJAX), CLICKHERETO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On June 13, 2025, the Fund abruptly slashed the value of its shares by 30%, with the value of shares continuing to fall in subsequent days. Industry news source The Bond Buyer reported the collapse was indicative of Fund-specific issues like 'flawed pricing,' 'illiquidity,' and the fact that the Fund was insufficiently 'diversified.' The article further noted that the Fund was heavily invested in junk investments with a 'lack of credit transparency.' According to the article, many bonds traded at a massive discount to their previously evaluated prices, including one instance where an investor paid just four cents for what had previous been represented as $3.2 million in bonds for a metal recycling company.
The total net assets of the Fund have collapsed from over $230 million as of March 31, 2025 to less than $17 million as of July 8, 2025.
Contact Us To Participate or Learn More:
If you purchased Easterly shares, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250724181316/en/
CONTACT: The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
[email protected]
www.frankcruzlaw.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL
SOURCE: The Law Offices of Frank R. Cruz
Copyright Business Wire 2025.
PUB: 07/24/2025 02:51 PM/DISC: 07/24/2025 02:51 PM
http://www.businesswire.com/news/home/20250724181316/en
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency
Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency

Yahoo

timean hour ago

  • Yahoo

Buy and Hold Investors Shouldn't Overlook Roper Technologies' (ROP) Consistency

Roper Technologies, Inc. (NASDAQ:ROP) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. A software developer looking out a window while confidently typing away on their laptop. Roper Technologies, Inc. (NASDAQ:ROP) is a group of technology businesses that hold strong positions in specialized niche markets. Its portfolio includes application software, network software, and technology-enabled products, all designed to deliver essential solutions that become deeply integrated into customers' operations. These offerings typically lead to high switching costs and generate steady, recurring revenue. In the second quarter of 2025, Roper Technologies, Inc. (NASDAQ:ROP) reported a 13.2% increase in revenue, driven by 7% organic growth and a 6% boost from recent acquisitions. GAAP net earnings rose by 12%. Management pointed to balanced growth across all major segments, crediting strong product innovation, successful integration of past acquisitions, and ongoing demand for recurring software solutions. Roper Technologies, Inc. (NASDAQ:ROP) has garnered investor attention because the company has a strong dividend policy. On June 11, the company declared a quarterly dividend of $0.825 per share, which was in line with its previous dividend. Overall, it has raised its payouts for 33 consecutive years, which makes ROP one of the best dividend stocks to buy and hold. The stock has a dividend yield of 0.60%, as of July 31. While we acknowledge the potential of ROP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Will VRTX Stock React To Its Upcoming Earnings?
How Will VRTX Stock React To Its Upcoming Earnings?

Forbes

timean hour ago

  • Forbes

How Will VRTX Stock React To Its Upcoming Earnings?

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements. The median positive return has been 3.0%, with a maximum one-day increase of 9.0%. For those trading based on events, recognizing these historical trends can prove advantageous, although actual performance against expectations will be crucial. There are two primary strategies to think about: Analysts anticipate Vertex will disclose earnings of $4.25 per share, generating a revenue of $2.91 billion. This marks a considerable improvement compared to the same quarter last year, which reported a loss of $12.83 per share on sales of $2.65 billion. However, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. View earnings reaction history of all stocks Vertex Pharmaceuticals' Historical Probability of Positive Post-Earnings Return Some insights regarding one-day (1D) post-earnings returns: Further information on observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized in the table below along with the related statistics. Correlation Between 1D, 5D and 21D Historical Returns A comparatively lower-risk approach (though not effective if the correlation is weak) is to evaluate the correlation between short-term and medium-term returns after earnings, identify the pair that exhibits the strongest correlation, and perform the proper trade. For instance, if 1D and 5D display the highest correlation, a trader can place themselves "long" for the forthcoming 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on both a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D indicates the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (the combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for stakeholders. Additionally, if you're seeking upside with a more stable journey than an individual stock like Vertex Pharmaceuticals, think about the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception.

Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity
Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity

Business Insider

timean hour ago

  • Business Insider

Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity

In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Alphatec Holdings, with a price target of $20.00. The company's shares closed today at $13.77. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cronin is a 2-star analyst with an average return of 0.5% and a 45.74% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Vericel, and Orthofix. In addition to Canaccord Genuity, Alphatec Holdings also received a Buy from Lake Street's Ben Haynor in a report issued today. However, on July 30, TR | OpenAI – 4o reiterated a Hold rating on Alphatec Holdings (NASDAQ: ATEC). Based on Alphatec Holdings' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $169.18 million and a GAAP net loss of $51.91 million. In comparison, last year the company earned a revenue of $138.48 million and had a GAAP net loss of $48.5 million Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year. Most recently, in May 2025, Scott Lish, the COO of ATEC sold 12,000.00 shares for a total of $145,440.00.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store